Table 1

Measurements of efficacy at baseline, week 8, week 16 and week 24

Measurements	Baseline	Week 8	Week 16	Week 24
PASI	11.8 (10.0–26.6)	2.7 (0.4–5.4)^*	1.8 (0.0–4.0)^*	1.2 (0.0–4.0)^*
Patient global assessment (VAS, mm)	50 (20–82)	30 (5–50)^*	25 (0–40)^*	15 (0–40)^*
Patient skin assessment (VAS, mm)	50 (30–94)	32 (15–50)^*	14 (0–37)^*	10 (0–37)^*
Physician global assessment (VAS, mm)	45 (10–71)	25 (5–53)^*	15 (0–42)^*	10 (0–32)^*
Physician skin assessment (VAS, mm)	53 (23–81)	22 (8–40)^*	10 (0–42)^*	8 (0–42)^*
Tender joints (n)	0 (0–2)	0 (0–2)	0 (0–1)	0 (0–1)
Swollen joints (n)	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–1)
Dactylitis (n)	0 (0–0)	0 (0–0)	0 (0–0)	0 (0–0)
MASES	0 (0–2)	0 (0–0)	0 (0–0)	0 (0–0)
ESR (mm/h)	14 (11–45)	16 (2–42)	16 (4–40)	18 (6–40)
CRP (mg/l, normal <5.0)	4.5 (0.4–14.0)	3.0 (0.4–15.0)	3.5 (0.5–7.0)	3.0 (0.6–5.1)

Values are median (range).
↵* p<0.05 (Wilcoxon test vs baseline).
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score7; PASI, Psoriasis Area and Severity Index6; VAS, visual analogue scale ranging from 0 (very well) to 100 mm (very poor).